
HeartFlow Inc (HTFL) Stock Forecast & Price Target
HeartFlow Inc (HTFL) Analyst Ratings
Bulls say
HeartFlow is in a strong position to continue delivering excellent performance and revenue growth, driven by its core US FFRCT business and the rapidly ramping-up emerging plaque business. The company's premium valuation is warranted considering its current momentum and projected growth, as well as its potential to expand its market by approximately $6 billion through upcoming clinical trials. We anticipate that HeartFlow's revenue will continue to be concentrated in its FFRCT business as it works to gain commercial reimbursement and adoption of its plaque product, but the potential for its plaque product to take off poses a positive outlook for margin expansion and future financial success. However, there are potential risks related to competition, reimbursement changes, and adoption of new technologies that the company should continue to address in order to maintain its strong position in the market.
Bears say
HeartFlow is experiencing positive momentum in its business operations, specifically in new account activations, ordering physicians, and Plaque utilization. Their Plaque analysis software has the potential to become their largest source of revenue with high gross margins. This could result in significant value for the company over the next few years. However, it is important to note that the broader adoption of the platform may be impacted by competitive forces, and the financials do not account for potential challenges in this area.
This aggregate rating is based on analysts' research of HeartFlow Inc and is not a guaranteed prediction by Public.com or investment advice.
HeartFlow Inc (HTFL) Analyst Forecast & Price Prediction
Start investing in HeartFlow Inc (HTFL)
Order type
Buy in
Order amount
Est. shares
0 shares